evidence table

Beta Alanine Reaction Time Randomized Trial Evidence Table

Structured evidence table for Beta Alanine Reaction Time Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Beta Alanine Reaction Time Randomized TrialImportantly, mechanistic evidence indicates that performance loss during repeated maximal efforts reflects an integrated disturbance in muscle function—encompassing substrate availability, metabolite/ionic perturbations, excitation–contraction coupling, and only later, more pronounced acid–base disruption—rather than a single dominant metabolite (–).1Liang Weibao (2026)No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
Beta Alanine Reaction Time Randomized TrialConsistent with this mechanism, contemporary meta-analytic evidence indicates the most reproducible ergogenic effects in high-intensity exercise tasks of approximately 1–4 min, where acid–base perturbation is more likely to be performance-limiting ().1Liang Weibao (2026)No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
Beta Alanine Reaction Time Randomized TrialBiopsy-based repeated-sprint experiments show that recovery of subsequent sprint performance is tightly associated with PCr resynthesis even when muscle pH remains depressed, suggesting that acid–base normalization is not a prerequisite for short-term restoration of repeated-sprint capacity (,).1Liang Weibao (2026)No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
Beta Alanine Reaction Time Randomized Trial1 2 3 4 5 7 Repeated sprint ability (RSA) is a defining performance attribute in intermittent sports, characterized by repeated maximal or near-maximal efforts separated by brief recovery, with an ensuing decline in mechanical output across bouts (,).1Liang Weibao (2026)No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
Beta Alanine Reaction Time Randomized TrialConclusion This rigorously designed trial is expected to generate reliable evidence.2Fu J (2026)Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.
Beta Alanine Reaction Time Randomized TrialBackground Type 2 diabetes mellitus (T2DM) has become a major global public health challenge, affecting more than 500 million adults worldwide.2Fu J (2026)Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.
Beta Alanine Reaction Time Randomized TrialEarly vascular aging (EVA) is one of the key pathological changes for diabetic vascular complications.2Fu J (2026)Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.
topicBeta Alanine Reaction Time Randomized Trial
claimImportantly, mechanistic evidence indicates that performance loss during repeated maximal efforts reflects an integrated disturbance in muscle function—encompassing substrate availability, metabolite/ionic perturbations, excitation–contraction coupling, and only later, more pronounced acid–base disruption—rather than a single dominant metabolite (–).
evidence level1
citationLiang Weibao (2026)
sourceNo ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
topicBeta Alanine Reaction Time Randomized Trial
claimConsistent with this mechanism, contemporary meta-analytic evidence indicates the most reproducible ergogenic effects in high-intensity exercise tasks of approximately 1–4 min, where acid–base perturbation is more likely to be performance-limiting ().
evidence level1
citationLiang Weibao (2026)
sourceNo ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
topicBeta Alanine Reaction Time Randomized Trial
claimBiopsy-based repeated-sprint experiments show that recovery of subsequent sprint performance is tightly associated with PCr resynthesis even when muscle pH remains depressed, suggesting that acid–base normalization is not a prerequisite for short-term restoration of repeated-sprint capacity (,).
evidence level1
citationLiang Weibao (2026)
sourceNo ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
topicBeta Alanine Reaction Time Randomized Trial
claim1 2 3 4 5 7 Repeated sprint ability (RSA) is a defining performance attribute in intermittent sports, characterized by repeated maximal or near-maximal efforts separated by brief recovery, with an ensuing decline in mechanical output across bouts (,).
evidence level1
citationLiang Weibao (2026)
sourceNo ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
topicBeta Alanine Reaction Time Randomized Trial
claimConclusion This rigorously designed trial is expected to generate reliable evidence.
evidence level2
citationFu J (2026)
sourceClinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.
topicBeta Alanine Reaction Time Randomized Trial
claimBackground Type 2 diabetes mellitus (T2DM) has become a major global public health challenge, affecting more than 500 million adults worldwide.
evidence level2
citationFu J (2026)
sourceClinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.
topicBeta Alanine Reaction Time Randomized Trial
claimEarly vascular aging (EVA) is one of the key pathological changes for diabetic vascular complications.
evidence level2
citationFu J (2026)
sourceClinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.

Learn next

Related evidence and supplement guides

GuideBeta Alanine Reaction Time Randomized Trial: What the Evidence SaysBeta Alanine Reaction Time Randomized Trial has 2 source documents in the current Migaku evidenc...GuideBacopa Reaction Time Randomized Trial: What the Evidence SaysBacopa Reaction Time Randomized Trial has 2 source documents in the current Migaku evidence data...GuideOmega-3 Reaction Time Randomized Trial: What the Evidence SaysOmega-3 Reaction Time Randomized Trial has 2 source documents in the current Migaku evidence dat...GuideCreatine Reaction Time Randomized Trial: What the Evidence SaysCreatine Reaction Time Randomized Trial has 2 source documents in the current Migaku evidence da...AnswerDoes Beta Alanine Reaction Time Randomized Trial work?Beta Alanine Reaction Time Randomized Trial has evidence relevant to strength of evidence and wh...AnswerIs Beta Alanine Reaction Time Randomized Trial safe?Beta Alanine Reaction Time Randomized Trial has evidence relevant to safety, limits, and clinici...AnswerWhat does the evidence say about Beta Alanine Reaction Time Randomized Trial?Beta Alanine Reaction Time Randomized Trial has evidence relevant to benefits, uncertainty, and...AnswerDoes Bacopa Reaction Time Randomized Trial work?Bacopa Reaction Time Randomized Trial has evidence relevant to strength of evidence and what the...

Source documents

  1. No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials
  2. Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol.